This treatment induced synergistic effects in breast (MCF7) cancer cells, inhibiting glycolytic activity by decreasing Glu uptake, GLUT1 and TIGAR expression, and ATP concentrations; it also synergistically increased the levels of RB, insulin-like growth factor-binding protein 3 (IGFBP3), and pAKT, leading to apoptosis by increasing Bax levels, caspase-9 activity, and PARP hydrolysis [319]. The gene discussed is IGFBP3; the disease is cancer.